Deborah A. Taira to Cost-Benefit Analysis
This is a "connection" page, showing publications Deborah A. Taira has written about Cost-Benefit Analysis.
Connection Strength
0.227
-
Lum CJ, Nakagawa K, Shohet RV, Seto TB, Taira DA. The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target. Hawaii J Med Public Health. 2017 04; 76(4):99-102.
Score: 0.142
-
Taira DA, Seto TB, Siegrist R, Cosgrove R, Berezin R, Cohen DJ. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J. 2003 Mar; 145(3):452-8.
Score: 0.054
-
Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW, Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation. 2001 Dec 18; 104(25):3039-45.
Score: 0.012
-
Seto TB, Taira DA, Manning WJ. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis. J Am Soc Echocardiogr. 1999 Jun; 12(6):508-16.
Score: 0.010
-
Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol. 1997 Jan; 29(1):122-30.
Score: 0.009